hrp0086rfc7.6 | Gonads & DSD | ESPE2016

The Hopeful Beginnings of Fertility Preservation in Children

Ho Cindy , Bourne Harold , Gook Debra , Clarke Gary , Kemertzis Matthew , Stern Kate , Agresta Franca , Zacharin Margaret , Heloury Yves , Clark Hannah , Orme Lisa , Barak Shlomi , Jayasinghe Yasmin

Background: Fertility Preservation (FP) in children and adolescents poses unique challenges as efficacy is unproven.Objective and hypotheses: To describe characteristics and evidence for potential fertility in ovarian and testicular tissue cryopreservation specimens (OTCP and TTCP respectively) taken from paediatric and adolescent patients, stratified by age, and prior chemotherapy.Method: Retrospective review of gonadal biopsies a...

hrp0094fc6.4 | Bone and Mineral Metabolism | ESPE2021

Use of Aids, Assistive Devices and Adaptations (AADAs) by Individuals Aged <25 Years with Fibrodysplasia Ossificans Progressiva (FOP): 36-Month Results from a Global Natural History Study (NHS)

Hsiao Edward C. , Pignolo Robert J. , Baujat Genevieve , Brown Matthew A. , De Cunto Carmen , Keen Richard , Mukaddam Mona Al , Marino Rose , Houchard Aude , Kaplan Frederick S. ,

Background: Individuals with the ultra-rare genetic disorder FOP experience progressive heterotopic ossification. Median age at diagnosis is 5 years; patients are supported by multiple specialties. Most patients become immobilised by the third decade of life, requiring lifelong assistance. We characterise AADA use as an indicator of disease severity in younger individuals with FOP enrolled in a 36-month, prospective, global NHS (NCT02322255).<p class="abst...

hrp0094p1-51 | Bone B | ESPE2021

A Global Natural History Study (NHS) of Fibrodysplasia Ossificans Progressiva (FOP): Normal Long Bone Growth and Abnormalities in Younger Patients over 36 Months

Pignolo Robert J. , Baujat Genevieve , Brown Matthew A. , Cunto Carmen De , Hsiao Edward C. , Keen Richard , Mukaddam Mona Al , Marino Rose , Houchard Aude , Kaplan Frederick S. ,

Background: FOP is an ultra-rare, severely disabling genetic disorder characterised by progressive heterotopic ossification. The median age at diagnosis is 5 years and patients are supported by multiple specialties. We describe normal long bone growth changes and incidence of bone abnormalities in participants with FOP aged <18 years in a 3-year, prospective, global NHS (NCT02322255).Methods: Individuals with FOP age...

hrp0095p1-153 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Urinary gonadotrophins as markers of puberty in girls and boys during late childhood and adolescence: Evidence from the SCAMP Cohort

Spiers Alexander , Patjamontri Supitcha , B Smith Rachel , Shen Chen , B. Toledano Mireille , Faisal Ahmed S

Introduction: Urinary gonadotrophins measurement is a noninvasive method for evaluation of pubertal development and may have utility in population studies.Objectives: To investigate the utility of urinary gonadotrophins as a noninvasive biomarker of puberty in boys and girls.Methods: School-based adolescent cohort study with two time points for collecting school time urine samples ...

hrp0095p2-148 | GH and IGFs | ESPE2022

Height Velocity in Indonesian Children Receiving Growth Hormone Therapy

B Pulungan Aman , A Andarie Attika , Lestari Pramesti Dwi

Background: Short stature is one of the most common conditions referred to pediatric endocrinology clinics, and treatment with growth hormone (GH) is useful to improve height velocity and adult height, but response may be variable. Growth hormone therapy is indicated in several conditions in pediatric patients, including growth hormone deficiency (GHD) and children born short for gestational age (SGA). We investigated differences in treatment response in Indon...

hrp0092p1-363 | GH and IGFs (2) | ESPE2019

Metabolism of Somapacitan, a Long-Acting Growth Hormone Derivative, in Human Subjects

Damholt Birgitte B , Bjelke Mads , Helleberg Hans , Rasmussen Michael H

Background: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative developed for once-weekly administration in patients with GH deficiency (GHD). It consists of a human GH backbone, similar to endogenous human GH, with one amino acid substitution, attached to an albumin binder via a linker chain.Objective: Absorption, metabolism and excretion (AME) of somapacitan were investigated in a Phase 1 trial (...

hrp0089p2-p277 | Growth &amp; Syndromes P2 | ESPE2018

Pulling the Brakes – ‘Catch Down Growth’: A Phenomenon for Achieving Mid-parental Height Centile After Acquired, All-cause, Brain Injury

Kraus Fabian B T , Hindmarsh Peter C , Spoudeas Helen A

Introduction: Of any pituitary dysfunction following brain injury, growth hormone (GH) deficiency (GHD) is the most prevalent. The cut-point for defining GHD has been placed at 7 ng/mL representing optimum test performance. We hypothesised this cut-off may be set too low for genetically taller children with acquired brain injury, notably brain tumours, who demonstrate severe growth failure but repeatedly fail to meet diagnostic thresholds for GH replacement until several centi...

hrp0082p2-d3-387 | Fat Metabolism &amp; Obesity (2) | ESPE2014

Enhanced Liver Fibrosis Test in Obese Children with Ultrasound-Proven Steatosis

Sztefko Krystyna , Szybowska Patrycja , Wojcik Malgorzata , Starzyk Jerzy B

Background: Non-alcoholic fatty liver disease (NAFLD) in obese children is a diagnostic challenge. Presently recommended markers of liver steatosis and risk of progression to fibrosis are: ultrasound imaging (US) and liver aminotransferases (ALT and AST). Owing to the poor sensitivity of these tests, there is a need to search for biomarkers which could indicate early stages of NAFLD. The enhanced liver fibrosis test (ELF) based on the combination of serum concentration of hyal...

hrp0094p2-375 | Pituitary, neuroendocrinology and puberty | ESPE2021

Salivary sex steroids as markers of puberty in boys during late childhood and adolescence

Patjamontri Supitcha , Spiers Alexander , Smith Rachel B , Shen Chen , Adaway Jo , G Keevil Brian , Toledano Mireille B , Ahmed S Faisal ,

Introduction: Salivary androgens represent a non-invasive marker of puberty that may have utility in population studies as well as in the clinical arena.Objectives: To establish normal reference values of salivary androgens using LC-MS/MS and demonstrate the correlations between salivary androgens and pubertal development in boys.Methods: School-based adolescent cohort study with t...

hrp0097p1-262 | Fat, Metabolism and Obesity | ESPE2023

16p11.2 microdeletion: a common copy number variation (CNV) identified in a Portuguese pediatric cohort with syndromic obesity.

Rosmaninho-Salgado Joana , B. Sousa Sergio , M. Pires Luis , Ferreira Susana , B. Melo Joana , M. Carreira Isabel , M. Saraiva Jorge

Background: 16p11.2 microdeletion is most common chromosomal anomaly associated with syndromic obesity. The presence of a large number of flanking segmental duplications/low-copy repeat sequences with a high degree of sequence identity in the short arm of chromosome 16 (16p) leads to recurrent deletions and duplications as a consequence of non-allelic homologous recombination. A recurrent 600kb microdeletion is one of the most frequent genomic imbalances in 16...